Active-State Model of a Dopamine D2 Receptor - G\(_i\) Complex Stabilized by Aripiprazole-Type Partial Agonists

Ralf C. Kling\(^1\), Nuska Tschammer\(^1\), Harald Lanig\(^2\),\(^3\), Timothy Clark\(^2\),\(^4\), Peter Gmeiner\(^1\)*

\(^1\) Department of Chemistry and Pharmacy, Emil Fischer Center, Friedrich Alexander University, Erlangen, Germany, \(^2\) Department of Chemistry and Pharmacy, Computer Chemistry Center, Friedrich Alexander University, Erlangen, Germany, \(^3\) Central Institute for Scientific Computing, Friedrich Alexander University, Erlangen, Germany, \(^4\) Centre for Molecular Design, University of Portsmouth, King Henry Building, Portsmouth, United Kingdom

Abstract

Partial agonists exhibit a submaximal capacity to enhance the coupling of one receptor to an intracellular binding partner. Although a multitude of studies have reported different ligand-specific conformations for a given receptor, little is known about the mechanism by which different receptor conformations are connected to the capacity to activate the coupling to G-proteins. We have now performed molecular-dynamics simulations employing our recently described active-state homology model of the dopamine D\(_2\) receptor-G\(_i\) protein-complex coupled to the partial agonists aripiprazole and FAUC350, in order to understand the structural determinants of partial agonism better. We have compared our findings with our model of the D2R-G\(_i\) complex in the presence of the full agonist dopamine. The two partial agonists are capable of inducing different conformations of important structural motifs, including the extracellular loop regions, the binding pocket and, in particular, intracellular G-protein-binding domains. As G-protein-coupling to certain intracellular epitopes of the receptor is considered the key step of allosterically triggered nucleotide-exchange, it is tempting to assume that impaired coupling between the receptor and the G-protein caused by distinct ligand-specific conformations is a major determinant of partial agonist efficacy.

Introduction

G protein-coupled receptors (GPCRs) constitute an important class of membrane-bound glycoproteins that participate in the regulation of various physiological processes including heartbeat, breathing and our senses of vision, smell and taste [1]. By transmitting extracellular stimuli to the inside of the cell, GPCRs serve as linker molecules that connect ligand binding to the coupling of intracellular binding partners including G proteins or \(\beta\)-arrestins [2]. In its canonical signaling pathway, the activated neurotransmitter/hormone-occupied receptor couples to G proteins, thereby inducing conformational changes that give rise to nucleotide-exchange and culminate in various functional responses [3–6]. The efficacy of a given ligand refers to its capacity to enhance the coupling of one receptor to a particular intracellular effector protein, thereby inducing quantifiable cellular responses [7,8]. Depending on the extent of their functional response, ligands can be classified as neutral antagonists or inverse agonists, neither of which stimulates receptor activation, full agonists, which cause a cellular response that strongly resembles that of the endogenous ligand, and partial agonists, which exhibit submaximal effects even at saturating concentrations.

Partial agonism at dopamine D\(_2\) receptors (D2R) has been suggested to exert beneficial effects on schizophrenia, a chronic mental illness characterized by hypo- and hyperfunctions in monoamine neurotransmitter systems, including the mesolimbic and mesocortical dopaminergic pathways [9]. The dopamine receptor partial agonists aripiprazole and the drug candidate cariprazine represent promising options for the treatment of schizophrenia [10–12] because of their stabilizing effect on monoamine pathways, especially the dopaminergic pathways, and their atypical antipsychotic effect.

Understanding the molecular basis of partial agonism requires detailed insight into the impact of ligands with different efficacies on the conformation of a given receptor or receptor-effector complex. Indeed, earlier studies that explored the origin of partial agonism revealed a ligand-dependent modulation of micro-switches important for receptor activation [13,14] and specific ligand-specific conformations within receptor epitopes that include the orthosteric binding pocket, the extracellular loop (EL) region and areas of receptor-G protein coupling [14–20]. However, a structural study based on an active-state receptor coupled to an intracellular binding partner able to link ligand-specific receptor conformations to the capacity to activate a given effector has not yet been reported.

Significant progress in the field of GPCR-crystallography led the way to the elucidation of the crystal structure of the ternary D\(_2\) adrenergic receptor G\(_i\) protein complex [21], which provides an unprecedented framework for the investigation of ligand-induced receptor conformations and of receptor G protein interactions. Using this experimental structure as a template, we were able to generate active-state homology models of the dopamine D\(_2\)
receptor (D2R) in complex with Goα and the endogenous agonist dopamine. We used these models to explore the structural determinants of selective receptor-G protein coupling on the amino-acid level using microsecond molecular-dynamics (MD) simulations [22].

We now report long-term all-atom MD simulations of our D2R-Goα homology model designed to help understand the molecular basis of partial agonist activity better. The D2R-Goα model in a hydrated bilayer environment was coupled to the partial agonist aripiprazole and a structurally related 1,4-disubstituted aromatic piperazine, 1,4-DAP [23,24], FAUC350, which has been shown to induce a strongly impaired modulation of cAMP accumulation while activating ERK1/2 phosphorylation with moderate efficacy [25]. In this work, we have investigated the impact of aripiprazole and FAUC350 on the conformation of the ternary D2R-Goα-complex, focusing on the shape of the extracellular loop region, the binding pocket and receptor-G protein-binding epitopes and compared our findings with our homology model of the D2R-Goα-complex in presence of the full agonist dopamine. As in our previous work [22,26,27], we have performed single long simulations, rather than multiple shorter ones. This strategy allows us to avoid missing conformational changes that occur with a characteristic induction period, which either may be inherent to the natural system or be caused by a parameterized kinetic or thermodynamic structural bias of the force field towards “native” (i.e. X-ray or homology) protein structures.

**Results/Discussion**

**Molecular-dynamics Simulations of Ternary D2R-Goα-complexes Coupled to Dopamine, Aripiprazole and FAUC350**

MD simulations with the ternary dopamine D2R-Goα complex revealed a high degree of conformational flexibility for the χ1-angle of His393 [22] (atoms: C-Cα-Cβ-Cγ) [22], a crucial residue for D2R activation [25,28]. Despite this flexibility, a dihedral angle of around −60°, which was found almost continuously in the simulation denoted D2R-i coupled to the partial agonists aripiprazole and FAUC350 (Table S1), turned out to be connected to favorable ligand-receptor, receptor-receptor and receptor-G protein-interactions (Figure S1). This simulation was used as a reference model with which to compare the simulations of D2R-Goα coupled to the partial agonists aripiprazole and FAUC350 (Tables S1 and S2). Starting from the existing membrane-inserted model, the dopamine ligand was removed and the partial agonists were docked. A more detailed description is given in the Materials and Methods section. The aripiprazole- and FAUC350-bound D2R-Goα complexes were subsequently submitted to energy minimization, equilibration and MD simulations runs of 800 ns and 500 ns, respectively. The G protein-motieties were more mobile than the receptor-units in both simulation systems (Figures S2 and S3). Nevertheless, the complexes showed no tendency for the G protein to dissociate from the receptor throughout the simulations (Figure S4).

**Aripiprazole and FAUC350 Open the Binding Pocket towards the Extracellular Surface**

The models show that dopamine and the phenylpiperazine moieties of aripiprazole and FAUC350 occupy the same orthosteric binding pocket, thereby interacting with residues of transmembrane helices (TM)s 3, 5, 6, 7 and EL2. The linker moieties of the partial agonists show additional interactions with residues located at an extended binding pocket closer to the extracellular surface of the receptor (Figures S5 and S6). Depending on the ligand, we observed differently shaped structures above the binding pocket (Figure 1), which appeared to close around the full agonist dopamine so that EL2 and the extracellular tail of TM7 (measured as the distance between residues Ile183 and Tyr7.35, Figure S7) are close to each other. In contrast, the partial agonists aripiprazole and, even more, FAUC350 opened up the binding pocket to the extracellular surface (Figure 1B). This opening is connected with the formation of a second binding pose for the partial agonist FAUC350 (Figures S2 and S5). Our observations are consistent with previous studies, which suggested ligand-specific conformations for EL2 and a regulatory function for this loop in receptor activation [29,30]. The pronounced movement of the extracellular tail of TM7 towards EL2 within the dopamine-complex can be attributed to a ligand-induced hydrogen bond between Ser5.43 and His6.55, which shifts the side chain of His6.55 in the direction of TM5 and clears a space for the inward movement of Tyr7.35 (Figure 1). Unlike dopamine, aripiprazole and FAUC350 lead to a different dihedral angle (approximately 60° and, mainly, 180°) for His6.55 (Figures 1A and 2A), thereby increasing the distance between Tyr7.35 and EL2.

**Ligand-specific Interhelical Networks**

Residue His6.55 was earlier found to play an important role in binding 1,4-DAPs, receptor activation and biased signaling [24,25,28]. The ligands dopamine, aripiprazole and FAUC350 can induce different conformations within the binding pocket of D2R by specifically adjusting the dihedral angle of His6.55 (Figure 2A). Thus, we attribute a key role to His6.55 in the ligand-dependent regulation of the binding pocket, which is consistent with experimental and computational reports. In addition to the ligand-specific conformational changes of His6.55, we captured differences in the interactions between the ligands and Ser5.42, Ser5.43 and Ser5.46 in TM5 (Figure S5). These residues have shown to be crucial for the binding of different ligands, including catecholamines, and for an effective receptor-G protein-coupling [31,32]. The full agonist dopamine formed stable hydrogen bonds to Ser5.42 and Ser5.46 and stabilized a conformation of Ser5.43, which facilitated hydrogen bonding to His6.55, while both aripiprazole and FAUC350 lacked hydrogen bonds to either serine residue and prevented the interaction between Ser5.43 and His6.55 (Figures 1 and S5). Moreover, the frequency with which the side chain of Ser5.43 pointed into the binding pocket was found to be reduced for aripiprazole and FAUC350 (Figure 2B). As receptor activation has been shown to be accompanied by such an inward movement of TM5-serines [33,34], the hindered engagement of these amino acids observed for aripiprazole and FAUC350 is likely to result in reduced activation. In general, the ligands investigated exerted different effects on specific conformations of amino-acid networks within the orthosteric binding pocket of D2R. Whereas the full agonist dopamine stabilized interactions between TM5 and TM6 close to the binding pocket, aripiprazole and FAUC350 led to helical reorientations such that TM6 moved away from TM5 towards TM7, thereby strengthening interactions between TM6 and TM7 and between TM7 and TM2 (Figure 2C, D). In contrast, interactions between TM3 and TM5, measured as a hydrogen bond between Thr3.37 and Ser5.46, remained mostly unmodified (Figure 2C).

The predicted binding modes for the endogenous agonist dopamine and the two partial agonists aripiprazole and FAUC350 differ significantly from that of the antagonist eticlopride in the crystal structure of the closely related dopamine D3 receptor (D3R) [35] (Figure S8). The full agonist dopamine is located deeper within the binding pocket of D2R than eticlopride (Figure S8A). In this conformation, the ammonium nitrogen of dopamine is stabilized by an ionic interaction to Asp3.32 and a cation-π interaction with Tyr7.35 and His6.55 (Figures 1A and 2A).
Figure 1. Ligand-specific conformations of the extracellular surface above the binding pocket. Representative snapshots of the dopamine- (left), the aripiprazole- (middle) and the FAUC350-complexes (right) are shown (average structures taken from 950–975 ns, 750–775 ns and 350–375 ns, respectively). (A) Extracellular view from the top into the binding pocket of the simulation systems. The ligands dopamine, aripiprazole and FAUC350 are highlighted in an orange, dark-grey and blue balls and sticks mode, respectively. The backbone of D2R is shown as ribbons, with important amino acids stabilizing the ligands indicated as sticks. (B) Side view into the binding pocket of the simulation systems, with a longitudinal section through the surface of D2R. Dopamine, aripiprazole and FAUC350 are represented as orange, dark-grey and blue balls and sticks, respectively. Compared to dopamine, both aripiprazole and FAUC350 open up the binding pocket towards the extracellular surface.

doi:10.1371/journal.pone.0100069.g001

Figure 2. Investigation of dihedral angles and hydrogen-bond networks within the ligand binding pocket of the simulation systems. (A) Ligand-specific regulation of the dihedral angle of residue His3935.55 (atoms: C-Cα-Cβ-Cγ), depicted as red, grey and blue lines for the dopamine-, the aripiprazole- and the FAUC350-complexes, respectively. (B) The dihedral angle of residue Ser1945.43 (atoms: C-Cα-Cβ-Cγ) within the dopamine-simulation is shown as red lines. Unlike a constant value observed within the dopamine system, both aripiprazole (left insert) and FAUC350 (right insert) cause a greater flexibility of this dihedral angle. (C) Hydrogen-bond interactions between representative residues of helices TM2, TM3, TM5, TM6 and TM7. Aripiprazole (grey values) and FAUC350 (blue values) cause a ligand-specific modulation within interhelical networks in proximity to the binding pocket compared to dopamine (red values). (D) Representative snapshots of D2R within the dopamine-, the aripiprazole- and the FAUC350-complexes shown as red, grey and blue ribbons, respectively. The snapshots represent average structures taken from 950–975 ns (dopamine), 750–775 ns (aripiprazole) and 350–375 ns (FAUC350). The superposition of these structures visualizes ligand-specific changes within interhelical networks in proximity to the binding pocket. Helix movements are indicated with green arrows.

doi:10.1371/journal.pone.0100069.g002
interaction to Phe\(^6.51\), thereby connecting TM3 and TM6 at residues that have been shown to be important for both ligand binding and receptor activation [24,36]. This connection between two helices that are relevant for activation is prevented by eticlopride because its positively charged nitrogen atom is displaced by 3.4 Å compared to its dopamine equivalent and its ethyl moiety helps shield the positive charge. Comparable but less pronounced displacements of the positively charged nitrogen atoms were observed in the partial agonist complexes (2.2 Å and 2.9 Å for aripiprazole and FAUC350, respectively) (Figure S8B and C). In these cases, it is still possible to connect helices TM3 and TM6 structurally, even though the conformation of Phe\(^6.51\) differs from that within the dopamine complex (and H2\(^6.50\) helps stabilize the charged nitrogen atoms by cation-π interactions). These observations thus suggest a more general role for the positively charged nitrogen atom of (partial) agonists in stabilizing the active-state of D2R in contrast to its role in the binding mode of antagonists such as eticlopride. Further studies of N-substituted agonists are needed in order to explore the possible conformational influences of the structural connections around the protonated nitrogen on receptor activation.

A Hydrophobic Network Connects the Ligand- and the G Protein-binding Pockets and is Regulated Differently by the Ligands

Ligand-binding to the extracellular part of the receptor is connected to conformational changes on its intracellular side [37], which points to the existence of an allosteric communication path that transforms rather small changes within the orthosteric binding pocket into pronounced intracellular rearrangements [38–41]. Earlier studies have identified hydrophobic residues at the core of TM3, TM5, TM6 and TM7 to be involved in this signal propagation; key roles in receptor activation were attributed to the so called ‘transmission switch’, consisting of Ile\(^6.30\), Pro\(^5.50\) and Phe\(^6.44\)[39], and the ‘rotamer toggle switch’, centered around Trp\(^6.48\)[42,43]. Consistent with these studies, our MD simulations depicted an allosteric communication network that links the ligand-binding pocket to the G-protein-coupling domain (Figure 3A, B). Starting from distinct dihedral angles of His\(^6.55\) within the binding pocket, we observed ligand-specific conformational changes of individual residues of this network (Figure S9), including the aromatic amino acids Phe\(^6.44\), Trp\(^6.48\) and Phe\(^6.52\), which are known to be crucial for receptor activation [39,40,44,45]. The lower end of this network is formed by the highly conserved residues Tyr\(^7.40\) and Tyr\(^7.53\) (Figure 3C), which were suggested to stabilize the active-state of the receptor via a water-mediated hydrogen-bond [46,47]. In analogy, it was found that mutation of Tyr\(^7.40\) in rhodopsin is involved in allosteric coupling to EL2[40] and in a reduction in the capacity to activate transducing [49]. Whereas the hydrogen bond between Tyr\(^7.40\) and Tyr\(^7.53\) remained stable throughout the dopamine-simulation, aripiprazole and FAUC350 caused a larger fluctuation in the distance between these residues (Figure 3D).

Full and Partial Agonists Influence the Conformation of G Protein-binding Epitopes of D2R Differently

Finally, ligand-specific conformational changes involve domains of receptor-G protein coupling. The crystal structure of a representative ternary signaling complex [21] provides us with a precise molecular understanding of the interactions between an activated receptor and its G protein. Numerous experimental studies indicated that some receptor-domains constitute critical determinants for the activation of G proteins, including intracellular loop 2 (IL2) [50], intracellular loop 3 (IL3, connected to the intracellular ends of TM5 and TM6) [51–54], the DRY-motif (located at the intracellular end of TM3) [55,56] and the proximal part of helix 8 (H8) [57]. Consequently, we analyzed the impact of our ligands on the conformation of these domains and found that the partial agonists aripiprazole and FAUC350 induce similar receptor conformations. However, these structures differ significantly from the receptor-dopamine complex (Figures 4 and 5A). One of these differences refers to the conformation of Met\(^140\)IL2, whose side chain formed contacts to the G protein in the dopamine simulation, but was directed away in the aripiprazole and FAUC350 complexes (Figures 4A–D and S10). Moreover, a computational alanine scanning analysis of this residue revealed an impaired stabilization of the receptor-G protein interface within the dopamine-complex, whereas the M140A mutation within the aripiprazole- and FAUC350-complexes exhibited weaker effects on receptor-G protein coupling (Figure S10), indicating a less important role for Met\(^140\)IL2 in stabilizing the receptor-G protein interface within the latter two simulation systems. These observations are consistent with experimental studies showing that mutation to alanine at the corresponding position of B2AR and the muscarinic receptors M1 and M3, resulting in a loss of interaction, was connected to a reduced capacity to activate G proteins [50]. IL2 is coupled structurally to the highly conserved DRY-motif at the intracellular end of TM3 (Figure 4A–C), which is known to be involved in G protein coupling via Arg\(^3.50\)[55,56]. In the case of the dopamine and aripiprazole complexes, although with a subtly rearranged architecture in the aripiprazole simulation due to a conformational change of IL2 around Met\(^140\) (Arg\(^3.50\) was stabilized by Arg\(^3.49\) and Tyr\(^142\)) and formed an ionic interaction to Asp\(^350\) of the C-terminal part of G\(_i\) (Figure 4A–C, Figure S11). This stabilizing triad was mainly broken in the FAUC350-simulation, resulting in a less stable salt bridge (Figure S11). In addition to the intracellular part of TM3, the C-terminus of G\(_i\), surrounded by the intracellular ends of TM5 and TM6 (constituting the beginning and the end of IL3, respectively) and the junction of TM7 and H8. Contacts of the C-terminus of G\(_i\) to the intracellular domain of TM5 were maintained throughout all three simulations (but with conformational changes for the open end of the N-terminal part of IL3) (Figures 4D and S12). However, the junction of TM7 and H8 moved away from the C-terminus of G\(_i\) in the aripiprazole and the FAUC350 complexes (Figure 4F). Moreover, cation-π (Lys\(^6.28\)/Phe\(^354\)) and hydrophobic interactions (Met\(^6.36\)) between residues of TM6 and the C-terminal part of G\(_i\) were reduced in the aripiprazole- and the FAUC350-binding models (Figure 4A–C and S13).

Taken together, the conformational changes described in the G protein-binding domains of D2R directly influenced the conformation of the interacting epitopes of G\(_i\), including the C-terminus, helices 6 and 7 and the loops 2N/β1 and 2β/3 (Figure 4). As it was recently shown that receptor-catalyzed nucleotide exchange is transmitted via dynamic changes within the linker regions connecting the areas of receptor-G protein and nucleotide-G protein-coupling [33], we hypothesize that a complete G protein activation requires specific intracellular receptor conformations, which can only be stabilized by a full agonist like dopamine (Figure 5A). Distinct partial agonist-induced differences in the way intracellular epitopes are shaped may lead to impaired receptor-G protein coupling and thus modulate the extent of the functional response (Figure 5B). It is therefore tempting to assume that impaired receptor-G protein coupling due to distinct ligand-specific conformations is a major determinant of partial agonist efficacy.
Figure 3. Hydrophobic network between the extracellular and the intracellular surface of D2R. The snapshots shown represent average structures taken from 950–975 ns (dopamine), 750–775 ns (aripiprazole) and 350–375 ns (FAUC350). (A, B) The backbone of D2R is shown as ribbons, important amino acids comprising the hydrophobic network are visualized as sticks. The ligands within their binding pockets are highlighted as dotted spheres. Superposition of representative snapshots taken from the dopamine- (red), the aripiprazole- (grey) and the FAUC350-simulations (blue) indicate ligand-specific conformations of residues within this hydrophobic network. (C) A water-mediated hydrogen bond between residues Tyr5.58 and Tyr7.53 (represented as sticks) of the crystal structure of β2AR bound to the ligand BI167107 and an intracellular nanobody (PDB-ID: 4LDE) is shown in green, with residue Arg1.50 forming the upper end of the G protein binding pocket. Additionally, representative snapshots of the dopamine- (red), the aripiprazole- (grey) and the FAUC350-simulations (blue) are superimposed with the crystal structure. (D) The distance between the hydroxyl groups of residues Tyr5.58 and Tyr7.53 within the dopamine-, the aripiprazole- and the FAUC350-complexes are shown as red, grey and blue lines, respectively.

doi:10.1371/journal.pone.0100069.g003

Figure 4. Crucial amino-acid interactions and conformational changes within G protein coupling domains. The backbone of D2R is shown as ribbons, whereas important amino acids are highlighted as sticks. The snapshots provided represent average structures taken from 950–975 ns (dopamine), 750–775 ns (aripiprazole) and 350–375 ns (FAUC350). (A–C) Crucial interactions between residues from the C-terminal part of Ga (Asp350, Phe354) and residues from the DRY-motif of TM3 (Asp3.49, Arg3.50), from IL2 (Met140, Tyr142) and from TM6 (Lys6.28, Met6.36) within representative snapshots of dopamine-, aripiprazole- and FAUC350-complexes are depicted in red, grey and blue, respectively. (D) A superposition of representative snapshots of dopamine-, aripiprazole- and FAUC350-complexes, represented in red, grey and blue, respectively, indicates conformational changes for residue Met140 of IL2 and for the N-terminal part of IL3. (E) Enlarged view of Figure 4d on the conformational changes of residue Met140 of IL2 within the simulation systems. A green arrow visualizes the movement of residue Met140. (F) A superposition of representative snapshots of dopamine-, aripiprazole- and FAUC350-complexes, represented in red, grey and blue, respectively, highlights the increasing distance of the intracellular part of TM3 and the junction of TM7 and H8, measured as the distance between the Cα-atoms of Ala135^S1.53 and ile431 of TM7/H8 (dashed box).

doi:10.1371/journal.pone.0100069.g004
Conclusions

In summary, we have used representative homology models of ternary receptor-G protein-complexes as structural scaffolds to investigate the molecular basis of partial agonism. We were able to capture distinct ligand-specific conformations within a homology model of our recently described ternary D2R-Gαi-complex, which help explain the graded efficacy of 1,4-DAP partial agonists such as aripiprazole and FAUC350 in comparison to the full agonist dopamine.

However, ligand-induced structural changes may differ for other receptor-effector systems such as receptor-β-arrestin-complexes [58] or even complexes of receptors with other G protein subtypes. This consideration is also relevant for both aripiprazole and FAUC350 in comparison to the full agonist dopamine.

Figure 5. Conformational changes within G protein coupling domains and their supposed effect on nucleotide release. (A) A summary of certain conformations of G protein coupling epitopes of D2R observed within the simulation systems is shown. (B–D) One representative snapshot of the dopamine-complex, taken as an average structure from between 950–975ns, is used as a scaffold, in which to compare the effect of the ligands dopamine, aripiprazole and FAUC350 on the conformation of G protein coupling domains and thus on nucleotide release schematically. Areas of receptor-G protein coupling are shown as dark-grey and light-grey ribbons, respectively. The conformation of GDP has been taken from a superposition of the aforementioned snapshot with the crystal structure of ground-state Gαi (PDB-ID: 1GP2). Stable contact regions of D2R are highlighted in green, conformational changes are indicated in orange. Colored arrows imply the supposed contribution of individual G protein coupling domains (contacts to α5: red, contacts to αN/β1: yellow, contacts to α4/β6/β6: violet) on nucleotide release (green arrows).

doi:10.1371/journal.pone.0100069.g005

One purpose of our work is to investigate the potential of long MD simulations for investigating complex biological processes, especially for GPCRs, for which experimental evidence is often sketchy. The simulations reported above are at the high end of what is possible today, appear inherently reasonable and offer rationalizations of experimental observations. We have concentrated on “hard” results (structures, persistent interactions) in the main text and have reported less well-founded data (e.g. MMPBSA results) in the Supporting Information in order to provide as reliable results as possible. However, the simulations are inherently stochastic (because of their starting velocities) and the force fields only moderately well tested for simulations of this length. In particular, our preferred strategy of using single long simulations is not without alternative.

Nevertheless, we believe that the simulations reported above are relevant for the real GPCR system and that they potentially provide new atomistic details that can now be tested experimentally.
Materials and Methods

Simulation Systems

The simulation systems contain our recently described active-site homology models of the dopamine D2 receptor (D2DowR and D2BPR), depending on the initial rotamer conformation of the side chain of residue His399 in the D2R models [22], which were based on the crystal structure of the β2-adrenergic receptor (B2AR) together with a heterotrimeric G-protein [21]. In addition, the models are embedded in a hydrated membrane consisting of dioleoylphosphatidylcholine (DOPC) lipids and coupled to the ligands dopamine, aripiprazole or FAUC350 (Tables S1 and S2).

Simulation A and B (Table S1) refer to previously published simulations of 1 μs each [22]. For simulation A, we performed an additional 500 ns simulation run as described [22].

Simulation systems C and D (Table S1) were prepared as follows: The ligands aripiprazole and FAUC350 were geometry optimized by means of Gaussian 09 [61] at the HF/6-31(d,p) level (attributing a formal charge of +1). AutoDock Vina [62] was used to subsequently dock both ligands into a membrane-inserted conformation of simulation system B. The ligand dopamine was removed before the docking procedure. We applied a search space of 28×26×40 Å to ensure a complete coverage of the binding pocket. The ligands were subjected to the docking procedure using an exhaustiveness value of 32 and a randomly selected starting position. 20 conformations of each ligand were obtained and inspected manually. Based on the scoring function of AutoDock Vina and experimental data, we selected one final conformation for each ligand. Parameter topology and coordinate files for the docked complexes were built up using the teclap module of AMBER10 [63] and subsequently converted into GROMACS input files [64,65]. We finally exchanged the coordinates of the ternary dopamine-D2AR-Gz1-complexes (system B) within the membrane-inserted simulation systems with those of the docked aripiprazole- and FAUC350-D2AR-Gz1-complexes. The final simulation systems contained 460 DOPC lipids surrounding the proteins and 8 chlorine atoms for charge neutralization. In total, systems C and D consisted of 227,577 atoms (51,300 water molecules) and 227,571 atoms (51,298 water molecules), respectively.

The final simulation systems were submitted to energy minimization (2500 steps of steepest descent minimization), equilibration (10 ns) and production molecular-dynamics simulation runs (300 ns and 500 ns for system C and D, respectively) using the GROMACS simulation package [64] as described earlier [26]. For all simulations, the general AMBER force field (GAFF) [66] was used for the ligands and the DOPC molecules and the force field ff99SB [67] for the protein residues. The GAFF force field for the lipids has been validated extensively by the original authors [68] and in our earlier work [22,26]. The SPC/E water model [69] was applied. Parameters for the ligands were assigned using antechamber [63] and charges were calculated using Gaussian 09 [61] at the HF/6-31(d,p) level and the RESP procedure according to the literature [70]. A formal charge of +1 was defined for the ligands. Throughout the productive simulations, a force of 1.0 kcal mol⁻¹ Å⁻² was applied to the N-terminal part of the G-protein’s αN-helix as described previously [22].

Data Analysis

We removed water and DOPC molecules for data analysis. The analysis of the trajectories was performed with the PTRAJ module of AMBER10 [63]. Calculation of the binding free energies was accomplished using MMPBSA. Py [71]. Figures were prepared using PyMOL [72] and Chimera [73].
The backbone of D2R is shown as ribbons, important amino-acids stabilizing the conformation of the ligands are represented as sticks. (A) A representative snapshot of the conformation of dopamine (orange balls and sticks) within the binding pocket is shown. (B) A representative snapshot of the conformation of aripiprazole (dark-grey balls and sticks) within the binding pocket is visualized. (C, D) Representative snapshots of the conformation of FAUC350 within the binding pocket are highlighted, taken from within the last 20 ns of the simulation time (light-blue balls and sticks, C) and at 400 ns (blue balls and sticks, D). (TIFF)

Figure S6 Residues within the binding pocket of D2R interacting with the ligands. A detailed contact analysis of residues within the binding pocket of the simulation systems interacting with the ligands is provided. An amino acid is considered as forming a contact to a ligand when at least one atom of the amino acid approaches at least one atom of the ligand closer than 3.5 Å. The contacts are investigated throughout the simulated time scales. (TIFF)

Figure S7 Distance between EL2 and the extracellular end of TM7. The distances between the side chains of Ile183 of EL2 and Tyr408 for TM7 for the dopamine-, the aripiprazole- and the FAUC350-complex are shown in red, grey and blue, respectively. (TIFF)

Figure S8 Comparison of the predicted binding modes of our agonists at D2R with the conformation of the antagonist eticlopride at D3R. Side view into representative snapshots of the binding pockets of D2R and the crystal structure of D3R. The snapshots represent average structures taken from 950–975 ns (dopamine), 750–775 ns (aripiprazole) and 350–375 ns (FAUC350). The backbone of the receptors is shown as ribbons, the ligands and important amino acids (Asp3.32, Phe6.51 and His6.53) stabilizing their conformation are represented as sticks. The positively charged nitrogen atoms of the ligands are highlighted as blue balls, whereas the distances between these nitrogen atoms of the ligands are given in light pink. The figure shows an overlay of eticlopride (green) at D3R with dopamine (orange/red, A), aripiprazole (grey sticks, B) and FAUC350 (blue, C) at D2R. (TIFF)

Figure S9 Ligand-specific dihedral angles of representative residues comprising the hydrophobic network between the ligand and the G protein binding pockets. (A–H) Dihedral angles ( atoms: C-C-C-C) of important residues from the core of the hydrophobic network (Ile3.49, Tyr5.48, Phe6.44, Trp6.46, Phe6.51, Phe6.52, Tyr7.35, Tyr7.53), which connect the ligand and the G protein binding pockets of D2R, are shown as dark-red, dark-grey and dark-blue lines representing the dopamine-, the aripiprazole- and the FAUC350-complexes, respectively. In addition, the dihedral angle of residue Trp6.46 between atoms C-C-C-C (D) is provided as light-red, light-grey and light-blue lines for the dopamine-, the aripiprazole- and the FAUC350-complexes, respectively. (TIFF)

Figure S10 Investigations on residue Met140 of IL2. (A) A computational alanine scanning analysis for residue Met140 of IL2 is provided for the dopamine- (left), the aripiprazole- (middle) and the FAUC350-complexes (right). Whereas the M140A mutation within the dopamine-complex was connected to an impaired stabilization of the receptor-G protein interface, we observed weaker effects of this mutation within the aripiprazole- and the FAUC350-complexes indicating a less important role of Met140 within the latter two simulation systems. (B) The distance between the side chain of Met140 of IL2 and the Cα-atom of Ile343 of α5 for the dopamine- (left), the aripiprazole- (middle) and the FAUC350-complexes (right) is shown. An increasing distance between these residues indicates a conformation of Met140 exhibiting reduced contacts towards the G protein. (TIFF)

Figure S11 Distances between individual residues of TM3, IL2 and the α5 helix of the G protein. The distances between individual residues of TM3 (Asp3.49, Arg5.30, IL2 (Tyr142) and the α5 helix of the G protein (Asp350) are shown as red, grey and blue lines for the dopamine-, the aripiprazole- and the FAUC350-complexes, respectively. The distance between residues Arg5.30 and Asp350 of the G protein comprising a salt bridge (A), between residues Arg5.30 and Asp1.49 of TM3 (B), between residues Arg5.30 of TM3 and Tyr142 of IL2 (C) and between residues Asp5.49 of TM3 and Tyr142 of IL2 (D) is provided. (TIFF)

Figure S12 RMS-deviations and contact analysis of the TM5-IL3 region. (A) RMS-deviations for TM5 of D2R within the simulation systems are shown as red, grey and blue lines for the dopamine-, the aripiprazole- and the FAUC350-complexes, respectively. The values attribute a low conformational flexibility to TM5. (B) RMS-deviations for the proximal part of IL3 of D2R within the simulation systems are shown as red, grey and blue lines for the dopamine-, the aripiprazole- and the FAUC350-complexes, respectively. The values indicate a high conformational flexibility for IL3. (C, D) A detailed contact analysis between residues of TM5 and IL3 of D2R interacting with residues of the G protein is provided. An amino acid is considered as forming a contact when at least one atom of one amino acid approaches at least one atom of a second amino acid closer than 3.5 Å. The contacts are investigated throughout the simulated time scales. (TIFF)

Figure S13 Investigation of TM6 residues Lys367 and Met374 and Met374. (A) The distances between TM6 residue Lys367 and Met374 of D2R and the C-terminal residue Phe354 of Gα are shown. (B) The distances between D2R residues Arg132 and Met374 are shown. Values are represented in red, grey and blue for the dopamine-, the aripiprazole- and the FAUC350-complex, respectively. (TIFF)

Table S1 Overview of the simulation systems and their simulated time scales. (DOCX)

Table S2 Chemical structures of the ligands investigated. (DOCX)

Author Contributions
Conceived and designed the experiments: RCK HL TC PG. Performed the experiments: RCK. Analyzed the data: RCK NT HL TC. Contributed to the writing of the manuscript: RCK NT HL TC PG.
References

1. Katritch V, Cherezov V, Stevens RC (2012) Structure-Function of the G Protein-Coupled Receptor Superfamily. Annu Rev Pharmacol Toxicol 53: 531–566.

2. Pierce KL, Premont RT, Lifkowitz RJ (2002) Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3: 639–650.

3. Chung KY, Rasmussen SG, Liu T, Li S, DeVreere BT, et al. (2011) Conformational changes in the G protein Gs induced by the beta(2)-adrenergic receptor. Nature 477: 611–615.

4. Westfield GH, Rasmussen SG, Su M, Dutta S, Devreere BT, et al. (2011) Structural flexibility of the G(alphai3)-helical domain in the beta(2)-adrenergic Gs complex. Proceedings of the National Academy of Sciences of the United States of America 108: 16058–16069.

5. Preininger AM, Meiler J, Hamm HE (2008) Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Mol Cell Biol 9: 60–71.

6. Oldham WM, Hamm HE (2008) Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Drug Discov 1: 103–110.

7. Galandrin S, Oligny-Longpre G, Bouvier M (2007) The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci 28: 423–430.

8. Freedman R (2003) Schizophrenia. N Engl J Med 349: 1738–1749.

9. DeLeon A, Patel NC, Gramen ML, (2004) Aripiprazole: a comprehensive review of the Effect of the G-Protein and Diffusible Ligands on the major determinant of ligand-biased signaling in dopamine D2L receptor. Mol Pharmacol 8: e67244.

10. Kiss B, Horvath A, Nemethy Z, Schmidt E, Laszlovszky I, et al. (2010) Conformational differences between full and partial agonists: evidence for ligand-specific receptor conformations. J Pharmacol Exp Ther 297: 1218–1226.

11. Zurn A, Zabel U, Vilardaga JP, Schindelin H, Lohse MJ, et al. (2009) Loop plays a key role in receptor-G protein coupling. J Biol Chem 288: 12225–12232.

12. Kiss B, Horvath A, Nemethy Z, Schmidt E, Laszlovszky I, et al. (2010) Amphipathic alpha-helical domain in the beta2-adrenergic receptor. Nature 477: 611–615.

13. Prininger AM, Meiler J, Hamm HE (2008) Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Mol Cell Biol 9: 60–71.

14. Olive WM, Hamm HE (2008) Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Drug Discov 1: 103–110.

15. Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, et al. (2001) Engineering a GPCR-ligand pair that simulates the activation of D(2L) by Dopamine. J Am Chem Soc 133: 14890–14896.

16. Seifert R, Wenzel-Seifert K, Gether U, Kobilka BK (2001) Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations. J Pharmacol Exp Ther 297: 1218–1226.

17. Zurn A, Zabel U, Vilardaga JP, Schindelin H, Lohse MJ, et al. (2009) Loop plays a key role in receptor-G protein coupling. J Biol Chem 288: 12225–12232.

18. Niesen MJ, Bhattacharya S, Vaidehi N (2011) The role of conformational flexibility and structural dynamics in GPCR-mediated G protein activation: a perspective. J Mol Biol 425: 2293–2300.

19. West GM, Chien EY, Katritch V, Gatchalian J, Chalmers MJ, et al. (2011) Structural flexibility of the G(alpha)s {alpha}-helical domain in the beta(2)-adrenergic receptor. J Biol Chem 286: 48: 481–485.

20. Goetz A, Lanig H, Gmeiner P, Clark T (2011) Molecular Dynamics Simulations of the Effect of the G-Protein and Diffusible Ligands on the beta(2)-Adrenergic Receptor. Journal of molecular biology.

21. Wang T, Wallner E, Carnevale AP, Freimuss M (1993) Amylphatic alpha-helical structure does not predict the ability of receptor-derived synthetic peptides to interact with guaninucleotide-binding regulatory proteins. J Biol Chem 268: 4637–4642.
54. Nanoff C, Koppensteiner R, Yang Q, Fuerst E, Ahorn H, et al. (2006) The carboxyl terminus of the Galpha-subunit is the latch for triggered activation of heterotrimeric G proteins. Molecular pharmacology 69: 397–405.

55. Rovati GE, Capra V, Neubig RR (2007) The highly conserved DRY motif of class A G protein-coupled receptors: beyond the ground state. Mol Pharmacol 71: 959–964.

56. Schneider EH, Schnell D, Strasser A, Dove S, Seifert R (2010) Impact of the DRY motif and the missing “ionic lock” on constitutive activity and G-protein coupling of the human histamine H4 receptor. J Pharmacol Exp Ther 335: 382–392.

57. Kaye RG, Saltarini J, Pritch J, Stevens WC, Wuthrich K (2011) Helix 8 of the M1 muscarinic acetylcholine receptor: scanning mutagenesis delineates a G protein recognition site. Molecular pharmacology 79: 701–709.

58. Liu J, Horst R, Katriel V, Stevens WC, Wuthrich K (2012) Biased Signaling Pathways in beta2-Adrenergic Receptor Characterized by 19F-NMR. Molecular pharmacology 79: 701–709.

59. MultiChak F, Brosda J, Franke RT, Fink H, Moller D, et al. (2013) Pharmacological profile of 2-bromoterguride at human dopamine D2, porcine serotonin 5-hydroxytryptamine 2A, and alpha2C-adrenergic receptors, and its antipsychotic-like effects in rats. J Pharmacol Exp Ther 347: 57-60.

60. Berendsen HJC, Grigera JR, Straatsma TP (1987) The missing term in effective pair potentials. The Journal of Physical Chemistry 91: 6269–6271.

61. Bayly CI, Cieplak P, Cornell WD, Kollman PA (1993) A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. The Journal of Physical Chemistry 97: 10269–10280.

62. Miller JJ, Brice DD, Swails JM, Homeyer N, Gohlke H, et al. (2012) MMPSA: An Efficient Program for End-State Free Energy Calculations. Journal of Chemical Theory and Computation 8: 3314–3321.

63. Schrodinger LLC (2010) The PyMOL Molecular Graphics System, Version 1.3.1.